In Reply We appreciate the interest and comments by colleagues on our recent systematic review and meta-analysis comparing anti–programmed cell death 1 (PD-1) vs anti–programmed cell death ligand 1 (PD-L1) treatments in patients with cancer.1 Below is our brief response; answers for the other questions can be mostly found in the article and will not be addressed here because of the space limit.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Wang Z, Zhao Z, Wang J. Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer—Reply. JAMA Oncol. 2020;6(7):1116–1117. doi:10.1001/jamaoncol.2020.0646
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: